How to use this page
The mental-health side of vitiligo has its own research: depression, anxiety, and the practical question of when and how to ask for support. For dating, work, school, and family situations, the life and mind hub covers those directly.
If you want a script for one moment, I wrote those as their own guides. What to say when someone stares, and how to talk to your child, each have one.
Underneath all of it, the question is how you are actually doing.
Community ideas are labeled because they vary by person. They are options, not promises about how another person will respond.
What research says about depression
I read a 2017 review pooling 25 studies and 2,708 people with vitiligo. It found depression recorded in about one in four people using medical diagnostic codes. About one in three showed up using self-reported surveys.
People with vitiligo were significantly more likely to have depression than people without it in this pooled comparison. I read the review's own recommendation that clinicians actively check for depression in vitiligo care, and offer a referral when needed. That is not a fringe suggestion. It is the standard the research itself points to.
The studies included used different designs and measurement tools, and the review reported real differences between them. A pooled percentage describes the groups studied. It cannot diagnose you, and it cannot tell you whether you personally will experience depression.
Sources for the facts above: Evidence
What research says about anxiety
I read a 2020 review pooling 15 studies and 1,176 people with vitiligo. It found anxiety reported in about one in three people, more often in women than men.
I want to report that honestly, and not only as a bigger number. When this same review compared people with vitiligo to people without it, the difference was not statistically significant. That does not mean the anxiety people report is not real - a third of people reporting anxiety is a lot of people. It means this particular pooled comparison could not confirm that vitiligo itself raises anxiety risk above the general population.
Both things can be true: anxiety is commonly reported alongside vitiligo. Whether vitiligo causes more anxiety than the general population remains genuinely unsettled in this evidence.
Sources for the facts above: Evidence
You do not have to wait until it feels severe
I checked the guidelines, and they already ask clinicians to raise psychosocial impact as normal vitiligo care, not something reserved for a crisis.
You can ask for support when distress, shame, avoidance, sleep, or concentration are becoming hard - not only once things feel unmanageable. Asking is appropriate even if you are unsure what kind of help you want yet.
A dermatologist or primary-care clinician may be able to make a referral. Peer support - other people who have vitiligo - can genuinely help some people, but it works alongside professional care, not instead of it.
Sources for the facts above: Evidence Evidence
Ask your care teamIf you are in danger right now
If you are in danger right now, treat it as an emergency - that comes before anything else.
In the United States, call or text 988 for crisis support by call, text, or chat. If you think you are in immediate danger of harming yourself, contact emergency services or a crisis line where you are.
Crisis services differ by location; nothing here can identify the right local service or assess your safety. If you are not sure it counts as an emergency, treat it as one and reach out anyway.
Lived experience - varies by person
What people say about getting support
The decision to ask for help does not look the same for everyone, and it does not always happen right away.
Some people say a therapist or counselor helped them separate "how my skin looks" from "how I feel about myself." Vitiligo tends to fuse those into one problem. Others say a support group, in person or online, was what finally made the isolation feel less total.
People I have heard from describe waiting years before mentioning any of this to a clinician. It felt like a separate complaint from the skin itself, or a past appointment had already left them feeling dismissed. Bringing a specific question, like the ones below, can make that conversation easier to start.
Bring to your next visit
You can use these as written or change the words. Saving keeps a question on this device.
Can we talk about how vitiligo is affecting my mood, sleep, or day-to-day life as part of my care?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Given how commonly depression and anxiety are reported alongside vitiligo, would a referral for extra support make sense now, rather than waiting?
Saving keeps this on your device and needs JavaScript, which is off in this browser.If I am not in crisis but this is wearing me down, what are my options?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- British Journal of Dermatology (Lai YC, Yew YW, Kennedy C, Schwartz RA)Systematic review · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict-of-interest disclosures were not verified beyond the published abstract; the full text was not accessible to check.
What this source supports
Supports that a pooled review of 25 studies (2,708 people with vitiligo) found depression recorded at about one in four people (25.3%, 95% CI 16-34%) by diagnostic codes. It supports about one in three (33.6%, 95% CI 25-42%) by self-report questionnaires. It supports that people with vitiligo were more likely to have depression than people without it. It supports that the review's authors recommend clinicians check for depression and offer a referral.
What it does not support
Does not diagnose any one person or predict any individual's risk. Does not establish why the association exists. The review reports differences between the included studies. Data of this kind cannot show that vitiligo causes depression. Funding and conflicts of interest for the studies were not checked beyond the published abstract.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- PLOS ONE (Kussainova A, Kassym L, Akhmetova A, Glushkova N, Sabirov U, Adilgozhina S, Tuleutayeva R, Semenova Y)Systematic review · Clinical research, tier 2Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: Funding and conflict-of-interest disclosures were not verified beyond the published abstract and results summary.
What this source supports
Supports that a pooled review of 15 cross-sectional studies (1,176 people with vitiligo) found anxiety reported in 35.8% of people with vitiligo overall. It supports a higher rate in women (47.32%) than men (42.4%). It supports that the rate varied widely by region (13.73% to 33.29%). It supports that anxiety-screening tools varied widely across the studies.
What it does not support
Does not establish that vitiligo raises anxiety risk above the general population. This review's own comparison against people without vitiligo (odds ratio 1.13, 95% CI 0.75-1.70) was not statistically significant. Does not diagnose any one person or predict an individual's risk. The studies used many different screening tools, which the authors say may explain some of the spread in results.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
- National Institute of Mental HealthPatient education · Patient education, tier 5Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports seeking professional help when mental-health concerns interfere with life and using the U.S.
What it does not support
988 Lifeline or emergency services when there are thoughts of self-harm or immediate danger. The source gives only a 2025 revision year; it does not diagnose a condition, assess an individual’s safety or provide crisis services outside the United States.
- World Health OrganizationPatient education · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports contacting emergency services or a crisis line when a person thinks they are in immediate danger of self-harm.
What it does not support
It does not identify a local service, assess an individual’s safety, or replace emergency help.